93,962 Shares in Amgen Inc. $AMGN Acquired by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 93,962 shares of the medical research company’s stock, valued at approximately $26,516,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. West Family Investments Inc. grew its position in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC raised its position in Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares during the last quarter. LOM Asset Management Ltd raised its position in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares during the last quarter. Sittner & Nelson LLC boosted its stake in Amgen by 0.4% during the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock worth $2,053,000 after purchasing an additional 30 shares during the period. Finally, TAGStone Capital Inc. grew its position in Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after purchasing an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen Trading Down 2.7%

NASDAQ AMGN opened at $351.48 on Thursday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $189.47 billion, a P/E ratio of 24.70, a P/E/G ratio of 3.58 and a beta of 0.45. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The firm has a 50-day moving average price of $359.46 and a 200 day moving average price of $326.94.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMGN. UBS Group upped their target price on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a report on Monday, January 26th. Wells Fargo & Company raised their price target on Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Mizuho upped their price objective on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Finally, Daiwa Securities Group increased their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.